PAP
ELDN icon

Persistent Asset Partners’s Eledon Pharmaceuticals ELDN Stock Holding History

Persistent Asset Partners’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-14,855
Closed -$40.3K – 261
2025
Q2 		$40.3K Hold
14,855
– – 0.03% 151
2025
Q1 		$50.4K Hold
14,855
– – 0.04% 134
2024
Q4 		$67.1K Buy
+14,855
New +$58.6K 0.06% 110

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
ZP
Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Persistent Asset Partners's ELDN Position: Q3 2025 in Review

Persistent Asset Partners sold out of Eledon Pharmaceuticals (ELDN) in Q3 2025, closing a stake of 14,855 shares — an estimated $40.3K sold.

Persistent Asset Partners first reported a position in ELDN in Q4 2024 and held it in 3 quarters. The position peaked at $67.1K in Q4 2024. 83 funds tracked by Wall St. Rank hold ELDN as of Q3 2025.

  • Persistent Asset Partners reported no remaining Eledon Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Persistent Asset Partners sold 14,855 Eledon Pharmaceuticals shares in Q3 2025, an estimated $40.3K.
  • Persistent Asset Partners first reported a position in Eledon Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • Persistent Asset Partners's Eledon Pharmaceuticals position peaked at $67.1K in Q4 2024.
  • 83 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q3 2025.

Based on Persistent Asset Partners's 13F filing for Q3 2025, filed 10 Nov 2025.